These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

674 related articles for article (PubMed ID: 30261606)

  • 41. Formyl peptide enhances cancer immunotherapy by activating antitumoral neutrophils, and T cells.
    Sun H; Li S; Wang Q; Luo C; Zhong L; Wan G; Li Z; Zhao G; Bu X; Zeng M; Feng G
    Biomed Pharmacother; 2024 Jun; 175():116670. PubMed ID: 38692065
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Second generation liposomal cancer therapeutics: transition from laboratory to clinic.
    Sen K; Mandal M
    Int J Pharm; 2013 May; 448(1):28-43. PubMed ID: 23500602
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tumour-selective drug delivery via folate receptor-targeted liposomes.
    Pan X; Lee RJ
    Expert Opin Drug Deliv; 2004 Nov; 1(1):7-17. PubMed ID: 16296717
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tumour Cell Secretome in Chemoresistance and Tumour Recurrence.
    Madden EC; Gorman AM; Logue SE; Samali A
    Trends Cancer; 2020 Jun; 6(6):489-505. PubMed ID: 32460003
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Liposomal delivery systems for anti-cancer analogues of vitamin E.
    Koudelka S; Turanek Knotigova P; Masek J; Prochazka L; Lukac R; Miller AD; Neuzil J; Turanek J
    J Control Release; 2015 Jun; 207():59-69. PubMed ID: 25861728
    [TBL] [Abstract][Full Text] [Related]  

  • 46. RGD peptide conjugated liposomal drug delivery system for enhance therapeutic efficacy in treating bone metastasis from prostate cancer.
    Wang F; Chen L; Zhang R; Chen Z; Zhu L
    J Control Release; 2014 Dec; 196():222-33. PubMed ID: 25456829
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Multimodal Molecular Imaging of the Tumour Microenvironment.
    Foray C; Barca C; Backhaus P; Schelhaas S; Winkeler A; Viel T; Schäfers M; Grauer O; Jacobs AH; Zinnhardt B
    Adv Exp Med Biol; 2020; 1225():71-87. PubMed ID: 32030648
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mathematical modelling of liposomal drug release to tumour.
    Chakravarty K; Dalal DC
    Math Biosci; 2018 Dec; 306():82-96. PubMed ID: 30391313
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Anti-neuropilin 1 antibody Fab' fragment conjugated liposomal docetaxel for active targeting of tumours.
    Manjappa AS; Goel PN; Gude RP; Ramachandra Murthy RS
    J Drug Target; 2014 Sep; 22(8):698-711. PubMed ID: 24766186
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Liposomal forms of anticancer agents beyond anthracyclines: present and future perspectives.
    Papachristos A; Pippa N; Ioannidis K; Sivolapenko G; Demetzos C
    J Liposome Res; 2015; 25(2):166-73. PubMed ID: 25148295
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer.
    Charrois GJ; Allen TM
    Biochim Biophys Acta; 2004 May; 1663(1-2):167-77. PubMed ID: 15157619
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Recent Advances in Nanoparticle-Based Targeted Drug-Delivery Systems Against Cancer and Role of Tumor Microenvironment.
    Ashfaq UA; Riaz M; Yasmeen E; Yousaf MZ
    Crit Rev Ther Drug Carrier Syst; 2017; 34(4):317-353. PubMed ID: 29199588
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Stimuli-responsive Smart Liposomes in Cancer Targeting.
    Jain A; Jain SK
    Curr Drug Targets; 2018 Feb; 19(3):259-270. PubMed ID: 26853324
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates.
    Allen TM; Mumbengegwi DR; Charrois GJ
    Clin Cancer Res; 2005 May; 11(9):3567-73. PubMed ID: 15867261
    [TBL] [Abstract][Full Text] [Related]  

  • 55. B-cell performance in chemotherapy: Unravelling the mystery of B-cell therapeutic potential.
    Li Z; Lin A; Gao Z; Jiang A; Xiong M; Song J; Liu Z; Cheng Q; Zhang J; Luo P
    Clin Transl Med; 2024 Jul; 14(7):e1761. PubMed ID: 38997802
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Triggered activation and release of liposomal prodrugs and drugs in cancer tissue by secretory phospholipase A2.
    Andresen TL; Jensen SS; Kaasgaard T; Jørgensen K
    Curr Drug Deliv; 2005 Oct; 2(4):353-62. PubMed ID: 16305438
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Monoclonal antibody-targeted PEGylated liposome-ICG encapsulating doxorubicin as a potential theranostic agent.
    Lozano N; Al-Ahmady ZS; Beziere NS; Ntziachristos V; Kostarelos K
    Int J Pharm; 2015 Mar; 482(1-2):2-10. PubMed ID: 25445515
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Therapeutic efficacy of the combination of doxorubicin-loaded liposomes with inertial cavitation generated by confocal ultrasound in AT2 Dunning rat tumour model.
    Mestas JL; Fowler RA; Evjen TJ; Somaglino L; Moussatov A; Ngo J; Chesnais S; Røgnvaldsson S; Fossheim SL; Nilssen EA; Lafon C
    J Drug Target; 2014 Sep; 22(8):688-97. PubMed ID: 24725154
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Liposomal nanomedicines in the treatment of prostate cancer.
    Kroon J; Metselaar JM; Storm G; van der Pluijm G
    Cancer Treat Rev; 2014 May; 40(4):578-84. PubMed ID: 24216226
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Use of nanotechnology for improved pharmacokinetics and activity of immunogenic cell death inducers used in cancer chemotherapy.
    Janicka M; Gubernator J
    Expert Opin Drug Deliv; 2017 Sep; 14(9):1059-1075. PubMed ID: 27897039
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.